key: cord-0077548-2xlp1r60
authors: Yetmar, Zachary A.; Khodadadi, Ryan B.; Seville, Maria Teresa; Brumble, Lisa; O’Horo, John C.; Ganesh, Ravindra; Razonable, Raymund R.
title: Outcomes of B-cell-depleted Patients with Coronavirus Disease 2019 Treated with Anti-spike Monoclonal Antibodies
date: 2022-04-14
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofac204
sha: 753ccd0bffb333b3f4c5ff1141ccc1a98c70c4bf
doc_id: 77548
cord_uid: 2xlp1r60

Anti-spike monoclonal antibody treatment of 180 B-cell-depleted patients with mild-to-moderate COVID-19 resulted in good outcomes overall, with only 12.2% progressing to severe disease, 9.4% requiring hospitalization, 0.6% requiring mechanical ventilation, no deaths within 30 days, and 1.8% developing persistent COVID-19. Anti-spike monoclonal antibodies appear effective in this immunocompromised population.

Anti-CD20 therapies, commonly used to treat B-cell malignancies, multiple sclerosis, and other 2 autoimmune disorders, result in severe humoral immunodeficiency that increases the risk for infectious 3 complications. During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, B-4 cell-depleted patients have been observed to be at high-risk for complications from coronavirus disease 5 2019 , including severe or persistent infection [1] [2] [3] . Due to their impaired humoral immune 6 response, there has been interest in antibody-based therapies for management of COVID-19 in this 7 population, including the use of high-titer convalescent plasma (ConvP) [4] [5] [6] . 8

Anti-spike monoclonal antibodies (mAb) have been the standard outpatient therapy for mild-to-9 moderate COVID-19 in patients with high-risk characteristics, including immunocompromised 10 populations [7, 8] . However, there is little data regarding outcomes following these therapies in B-cell-11 depleted patients. We sought to analyze our cohort of patients who received anti-CD20 therapies and 12 were treated early with mAbs for mild-to-moderate Methods 14

We conducted a multicenter, retrospective review of all B-cell-depleted patients diagnosed with 16 mild-to-moderate COVID-19 who received mAb therapy. Patients were ascertained from our internal 17 COVID-19 database for recipients of an anti-CD20 antibody and mAb from three Mayo Clinic sites in 18 Arizona, Florida, and Minnesota from November 9, 2020 through February 15, 2022. 19 Inclusion criteria were age ≥18 years and receipt of an anti-CD20 antibody within 12 months 20 prior to COVID-19 diagnosis. Exclusion criteria were last anti-CD20 infusion ≥12 months before COVID-19 21 diagnosis, lack of COVID-19 confirmation by SARS-CoV-2 polymerase chain reaction (PCR) or antigen 22

testing, or lack of research authorization. Data were manually extracted from the electronic medical 1 record, including demographics, anti-CD20 therapy, COVID-19 diagnosis and therapies, and outcome 2 measures. 3

The primary outcome of this study was progression to severe COVID-19, defined as hypoxia 4 (oxygen saturation ≤94% or supplemental oxygen requirement above baseline) or hospitalization for 5 COVID-19. High-risk outpatients with COVID-19 are routinely offered remote monitoring during their 6 isolation period, which includes medical equipment to monitor vital signs and oxygen saturation and 7 dedicated nursing teams to perform phone visits with patients. Secondary outcomes were emergency 8 department (ED) visits, intensive care unit (ICU) admission, and persistent COVID-19. Persistent COVID-9

19 was defined as a positive SARS-CoV-2 PCR or antigen test 30-90 days after index diagnosis with 10 compatible clinical symptoms and lack of an alternative explanation [9] . Date of COVID-19 diagnosis was 11 defined as the date a positive SARS-CoV-2 assay was collected. Outcomes were also compared based on 12 the dominant variant of concern (VOC) at the time of COVID-19 diagnosis. Those One-hundred and eighty patients met inclusion criteria; 163 patients were receiving rituximab 5 and 17 obinutuzumab ( Table 1 ). The most common mAb was casirivimab-imdevimab (45.0%), followed 6 by sotrovimab (33.3%). All patients had at least 30 days of follow-up after COVID-19 diagnosis. Twenty-7 two (12.2%) patients developed severe COVID-19, including 17 (9.4%) who required an ED visit and 17 8 (9.4%) who required hospitalization. Among 17 patients who were hospitalized, 16 were treated with 9 remdesivir, 13 received corticosteroids, and 1 received ConvP. No patients received baricitinib or 10 tocilizumab. One patient (0.6%) required ICU admission and mechanical ventilation. No other patients 11 required non-invasive ventilatory support or high-flow oxygen support. No patients died within 30 days 12 of COVID-19 diagnosis. 13

Only dyspnea at diagnosis was associated with progression to severe COVID-19 (p=.002). 14 Monoclonal Antibody Screening Score and Charlson comorbidity index were similar between patients 15 who developed severe COVOD-19 and those who remained with mild to moderate COVID-19 16 (Supplementary Table 1 ). There was no significant difference in the rates of severe COVID-19 17 progression based on the type of mAb. The mAbs used based on dominant VOC is presented in Figure 1 . 18

The rate of progression to severe COVID-19 was highest in the pre-Delta era (17.6%), followed by Delta 19 (13.3%), and Omicron (8.0%), but these were not significantly different (p=.417). Eleven patients had 20 anti-spike antibody titers measured prior to mAb receipt and 7 were positive. 21

Of 111 patients with at least 90 days of follow-up, two (1.8%) developed persistent COVID-19. 2

Both patients had not received any dose of SARS-CoV-2 vaccine. The first patient was an 81-year-old 3 female with diffuse large B-cell lymphoma who was receiving rituximab, cyclophosphamide, 4 daunorubicin, vincristine, and prednisone. She initially presented with cough, fever, and chills and 5 received bamlanivimab 2 days after onset. Her symptoms were initially mild and improved without 6 other therapies. However, she was admitted 36 days after initial diagnosis with escalating dyspnea. 7

Computed tomography (CT) of the chest showed multifocal peripheral ground-glass and tree-in-bud 8 opacifications. Despite initiation of remdesivir, dexamethasone, and broad-spectrum empiric antibiotics, 9

she experienced progressive respiratory failure. Microbiologic testing from a bronchoalveolar lavage 10 (BAL) was uniformly negative for microbial pathogens except for positive SARS-CoV-2 PCR. After 19 days 11 of hospitalization, she was transitioned to comfort care and died thereafter. 12

The second patient was a 72-year-old female with a history of kidney transplantation 6 months 13 prior, maintained on tacrolimus, mycophenolate mofetil, and prednisone, who was receiving rituximab 14 for allograft membranous nephropathy. She tested positive for SARS-CoV-2 when she presented with 15 cough and dyspnea. She received casirivimab-imdevimab 4 days after symptom onset. Twelve days later, 16 she was hospitalized due to hypoxia and received remdesivir. After initial clinical improvement, she was 17 readmitted 29 days later due to hypoxia where chest CT showed peripherally based ground-glass and 18 consolidative opacifications. She underwent BAL, where SARS-CoV-2 PCR was positive while all other 19 microbiologic testing was negative. She did not receive further COVID-19 therapy. She was re-admitted 20 again 57 days after diagnosis where BAL sampling was again positive only for SARS-CoV-2. She 21 developed progressive hypoxia and died after a 4-day hospitalization. 22

We describe the clinical outcomes of COVID-19 in B-cell-depleted patients with initial mild-to-2 moderate infection who were treated with mAb. Overall, most patients experienced favorable outcomes 3 within the first 30 days following infection. In contrast to prior reports, only 12.2% of our cohort 4 progressed to severe disease and 9.4% required hospitalization. Dyspnea on initial presentation was 5 associated with progression to severe disease, which may be reflective of lower respiratory involvement 6 that is already too advanced for mAb therapy. Despite 9.4% requiring hospitalization, the outcomes 7 remained favorable at 30 days, with only one patient requiring ICU admission or invasive ventilation. No 8 patient died within 30 days of treatment. 9

Anti-spike mAbs have consistently shown efficacy in many other cohorts of high-risk patients 10 [7,10,11]. In a single-center study of immunocompromised patients with cancer, primarily hematologic 11 malignancies, 43 patients who received mAb therapy had a hospitalization rate of 12% and only one 12 patient required ICU care or died of . Comparable outcomes were shown in solid organ 13 transplant recipients and those with other high-risk comorbidities [7, 8, 10, 11] [4] . Collectively, early administration of antibody-based therapy is the recommended approach for B-cell 4 depleted patients with mild to moderate COVID-19. Notably, our cohort was infused mAb at a median of 5 4 days after the onset of symptoms. Providing mAb early in the disease course may partly account for 6 the favorable outcomes in our cohort. Designing systems to rapidly diagnose and treat those at highest 7 risk is key to optimizing clinical outcomes. 8

The rates of progression to severe COVID-19 seemed to numerically decline over time with the 9 evolution of SARS-CoV-2 VOC. However, this was not a statistically significant observation. While this 10 analysis of outcomes may have been underpowered, there were also important advances in 11 management of COVID-19 through time, including the opportunity for primary SARS-CoV-2 vaccination. 12

The 30-day outcomes in our cohort were improved compared to historical cohorts, but it should 13 also be noted that two patients who developed persistent COVID-19 ultimately died from their infection 14 within 60 days of initial diagnosis. While mAbs appear beneficial in the early phases of disease, the 15 optimal management of persistent infection remains unclear and the role of mAbs in this setting 16 requires further study. Knowledge of the specific SARS-CoV-2 VOC in patients with persistent infection 17 may be an important strategy to determine if there is a VOC-mAb mismatch that accounts for the poor 18 clinical outcome. 19

A limitation of this study is its retrospective observational design with sources of bias inherent 20 to this study type. There was very little data on baseline serostatus, limiting our ability to examine 21 association of outcomes with pre-existing anti-spike antibody titers. The study was conducted through 22

February 15, 2022, prior to the emergence of the BA.2 Omicron variant. While mAbs used were effective 23

at the time of the study, many are no longer effective against the currently surging BA.2 Omicron VOC. 1

The rise of BA.2 Omicron has paused the clinical use of sotrovimab. Our program currently only utilizes 2 bebtelovimab for B-cell-depleted patients with mild-to-moderate COVID-19 since it remains effective 3 against Omicron. Finally, we can only assume, but not confirm, effectiveness since our study does not 4 have a comparator group. The high uptake of mAb among our immunocompromised populations made 5 it impossible to identify a comparable contemporary group of untreated B-cell-depleted patients. Thus, 6

while clinical outcomes of our cohort were improved compared to outcomes reported in prior studies, 7 these indirect comparisons should be interpreted with caution. 8

In conclusion, this study of 180 immunocompromised B cell-depleted patients with COVID-19 9 demonstrated low rates of progression to severe disease, hospitalization, ICU admission, mortality, and 10 persistent infection when treated early with mAb. The use of mAb should be encouraged in this highly 11 vulnerable population. 12 acute respiratory syndrome coronavirus 2; SD, standard deviation; VOC, variant of concern; y, years. 5 a Defined as an estimated glomerular filtration rate <60 mL/min/1.73 m 2 as calculated by the 2021 CKD-6 EPI equation. N = 179, excluding 1 patient who did not have renal function testing. 7 Includes 4 kidney transplant recipients, 2 heart transplant recipients, 2 liver transplant recipients, 1 1 lung transplant recipient, and 1 kidney-pancreas transplant recipient. 2 c Third SARS-Cov-2 vaccine dose defined as receipt of an mRNA vaccine dose following either 2 prior 3 mRNA vaccine doses or 1 adenovirus-vector dose. 4 d Other indications for anti-CD20 therapy included pemphigus vulgaris (2), membranous nephropathy (2), 5

antibody-mediated allograft rejection (2), focal segmental glomerulosclerosis recurrence after kidney 6 transplantation (1), and desensitization prior to heart transplantation (1). 7 e N = 167, excluding 13 patients who were diagnosed with COVID-19 during a VOC overlap period (4 in 8 June 2021; 9 in late December 2021). 9 10 A C C E P T E D M A N U S C R I P T

Bar chart demonstrating anti-spike monoclonal antibody usage during three periods divided by 2 dominant circulating SARS-CoV-2 variant of concern. 3 Pre-Delta period is November 2020-May 2021, Delta period is July 1 -December 15, 2021, and Omicron 4 period if January 1 -February 15, 2022. This chart includes 167 patients, excluding 13 patients who were 5 diagnosed during periods of overlap between variants of concern (excluded time: June 2021 and 6

December 1-15, 2021). 

Relapses and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Infection in Patients Treated With Anti-CD20 Monoclonal Antibodies

Prolonged SARS-CoV-2 Infection in Patients with Lymphoid 6

Disease-Modifying Therapies and Coronavirus Disease 8 2019 Severity in Multiple Sclerosis